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論文の内容の要旨 
Abstract of thesis 
 
In this doctoral dissertation, ZHANG XIN describes the role of TSC22D4/THG-1 in cellular senescence 




Esophageal cancer is the seventh most common cancer worldwide and the sixth most common cause of 
cancer-related death. Although the significant development of diagnostic methods and combined therapy in recent 
years has led to a more prolonged survival of esophageal SCC (ESCC) patients, the overall survival rate is still 
poor in the advanced stages. TSC22 homologous gene-1 (THG-1) is a member of the TGF-β 1 stimulated clone 22 
(TSC22) family, which is located at the basal layer in healthy cells but highly expressed in squamous cell 
carcinoma. The previous study in the applicant’s lab had already found that THG-1 has an essential role in 
tumorigenic activity in ESCC. As knockdown of THG-1 in ESCC shows a reduction of cell proliferation and the 
xenograft tumor size. However, the molecular mechanism of THG-1 in ESCC is still unknown. Therefore, the 
applicant aimed to generate THG-1 KO cell lines in this study to investigate the role of THG-1 in ESCC, and find 
an effective molecular targeting therapy to treat ESCC. 
 
（対象と方法 Materials and Methods） 
In this research, molecular biological experiments were performed. CRISPR/Cas9 gene-editing system was 
employed to generate THG-1 knockout (KO) in TE13 cell line. Senescence-associated β-galactosidase (SA-β-gal)  
 
-２ 
staining assay was performed to check the number of senescent positive cells. Western blotting was performed to 
examine the expression levels of proteins. Quantitative PCR (qPCR) was used to quantify mRNA expression 
levels. Immunofluorescence staining was used to investigate the localization of protein expression in each cell. 
Cell proliferation assay was used to check the cell growth condition. siRNA gene silencing was performed to 
knockdown JUNB in THG-1 KO cells. Short hairpin RNA (shRNA)-mediated THG-1 knockdown was used to 
confirm THG-1 function in ESCC. 
 
（結果 Results） 
The applicant successfully generated THG-1 KO cell lines by CRISPR/Cas9 gene-editing system in 
TE13 cells. THG-1 KO cells exhibited delayed cell proliferation and manifest accelerated senescent cell 
phenotypes such as cell size enlargement, SA-β-gal activity, and enhanced expression of P21(CDKN1A). 
Immunofluorescence staining detected P21 mainly in enlarged nuclei. Increased expression of JUNB was diffusely 
observed, and JUNB knockdown suppressed the expression of CDKN1A and SA--galactosidase activity. Besides, 
similar results were obtained by shRNA-mediated knockdown of THG-1 in TE13 cells and another ESCC cell line 
KYSE 1260, as THG-1 knockdown tended to stimulate the transcription of CDKN1A and JUNB and promote 
cellular senescence. Based on these results, the applicant concluded  that THG-1 suppresses cellular senescence 
at least partially through suppression of JUNB and subsequent suppression of CDKN1A. 
 
（考察 Discussion） 
Senescence is one of the critical tumor suppression mechanisms which limits cancer initiation and 
progression through various molecular pathways. In this study, the applicant found that THG-1 KO can activate 
cellular senescence in cancer cells though inducing P21 (CDKN1A) transcription, leading to increased protein 
levels, in a manner which is independent of P53. The induction of P21 (CDKN1A) is thought to be crucial for the 
induction of cellular senescence in cancerous cells. P21 (CDKN1A) transcription is known to be regulated by JUN 
family proteins. In this study, JUNB was found to be involved in P21 (CDKN1A) induction and the induction of 
cellular senescence in THG-1 KO cells. It is important to note that the possibility of additional involvement of 
other factors in this process cannot be ruled out. JUN family proteins, including JUNB, have been reported to act 
as transcriptional activators of P21 (CDKN1A) and P16 (CDKN2A), and to regulate cell proliferation, 
differentiation, and stress responses. 
        Furthermore, JUNB expression is found to be low in human squamous cell carcinomas. Exogenous 
expression of JUNB inhibited tumorigenesis in these tumor cells. Therefore, the activation of JUNB in cancer 
cells is an essential factor in the suppression of cancer cell proliferation. Although the applicant identified the 
senescence pathway present in THG-1 KO cells, the mechanism that links THG-1 to JUNB has not been identified. 
It was confirmed that THG-1 mainly localizes in the cytoplasm, suggesting that THG-1 does not act as a direct 
transcriptional regulator. In the oncogene (BRAFE600)-induced cellular senescence model, TSC-22/TSC22D1 play 
crucial roles in the induction of oncogene-induced cellular senescence. Since THG-1 can bind to TSC-22, it may 
be antagonized by THG-1 in tumor cells. It was previously reported that TSC-22 promotes P21 (CDKN1A) 
promoter activity through interaction with c-MYC in the nucleus. Further studies, including identifying THG-1 
binding partners and the mechanism of senescence induction by TSC-22, are required to understand the molecular 











（批評 General Comments） 
In the present study, the applicant first successfully established THG-1 KO in ESCC and found that 
THG-1 is involved in suppression of cellular senescence. Activation of JUNB-P21(CDKN1A) axis plays a crucial 
role on cellular senescence in THG-1 KO cells. These findings provide a novel insight into the induction of 
cellular senescence in ESCC, providing the possibility for future therapy including combination or synthetic lethal 
therapy to induce cellular senescence in ESCC. 
 
（最終試験の結果 Assessment） 
The final examination committee conducted a meeting as a final examination on 15 January, 2020. The 
applicant provided an overview of dissertation, addressed questions and comments raised during Q&A session. All 
of the committee members reached a final decision that the applicant has passed the final examination.  
 
（結論 Conclusion） 
The final examination committee approved that the applicant is qualified to be awarded Doctor of 
Philosophy in Medical Sciences. 
 
 
 
 
